Is Forte Biosciences, Inc. (FBRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 16.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 16.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 94.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 16.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 94.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -110.7% | |
| Return on Assets (ROA) | -58.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$31M |
| Free Cash Flow | -$31M |
| Current Ratio | 7.3 |
| Total Assets | $62M |
Price & Trading
| Last Close | $27.01 |
| 50-Day MA | $29.34 |
| 200-Day MA | $18.64 |
| Avg Volume | 205K |
| Beta | 3.2 |
|
52-Week Range
$4.90
| |
About Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Forte Biosciences, Inc. (FBRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Forte Biosciences, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Forte Biosciences, Inc.'s debt ratio?
Forte Biosciences, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Forte Biosciences, Inc.'s key financial metrics?
Forte Biosciences, Inc. has a market capitalization of $319M. Return on equity stands at -110.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.